An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 209899
Company: BRISTOL

Medication Guide

Products on NDA 209899

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
ZEPOSIA	OZANIMOD HYDROCHLORIDE	EQ 0.23MG BASE	CAPSULE;ORAL	Prescription	None	Yes	No
ZEPOSIA	OZANIMOD HYDROCHLORIDE	EQ 0.46MG BASE	CAPSULE;ORAL	Prescription	None	Yes	No
ZEPOSIA	OZANIMOD HYDROCHLORIDE	EQ 0.92MG BASE	CAPSULE;ORAL	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 209899

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/25/2020	ORIG-1	Approval	Type 1 - New Molecular Entity	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209899Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209899Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
08/10/2023	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209899s006s009lbl.pdf
08/10/2023	SUPPL-6	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209899s006s009lbl.pdf
09/29/2022	SUPPL-5	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209899s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209899Orig1s005ltr.pdf
12/15/2021	SUPPL-3	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209899s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209899Orig1s003ltr.pdf
05/27/2021	SUPPL-1	Efficacy-New Indication	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209899s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209899Orig1s001ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/209899Orig1s001.pdf

Labels for NDA 209899

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
08/10/2023	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209899s006s009lbl.pdf
08/10/2023	SUPPL-6	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209899s006s009lbl.pdf
09/29/2022	SUPPL-5	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209899s005lbl.pdf
12/15/2021	SUPPL-3	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209899s003lbl.pdf
12/15/2021	SUPPL-3	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209899s003lbl.pdf
05/27/2021	SUPPL-1	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209899s001lbl.pdf
03/25/2020	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf

Top